BLZ-100: Phase I started

Blaze began an open-label, U.S. Phase I trial of IV BLZ-100 in up to 21 patients with soft tissue sarcoma (STS) who are undergoing surgery. The first part will compare 3 and 12 mg doses given 2-3 days...